During the past decade, Praxis für interdisziplinäre Onkologie & Hämatologie conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Praxis für interdisziplinäre Onkologie & Hämatologie" #1 sponsor was "iOMEDICO AG" with 4 trials, followed by "Celgene" with 1 trials sponsored, "Dompé Farmaceutici S.p.A" with 1 trials sponsored, "Puma Biotechnology, Inc." with 1 trials sponsored and "Queen Mary University of London" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Praxis für interdisziplinäre Onkologie & Hämatologie" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Praxis für interdisziplinäre Onkologie & Hämatologie" are "Breast Cancer" (2 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Breast Cancer Female" (1 trials), "Breast Tumor" (1 trials) and "Cancer of the Breast" (1 trials). Many other conditions were trialed in "Praxis für interdisziplinäre Onkologie & Hämatologie" in a lesser frequency.

Most popular intervention types in "Praxis für interdisziplinäre Onkologie & Hämatologie" are "Drug" (7 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "AZD2014" (1 trials), "Abemaciclib 50 MG; 150mg 1-0-1 per os" (1 trials), "Budesonide" (1 trials), "Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Praxis für interdisziplinäre Onkologie & Hämatologie" are 6 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Praxis für interdisziplinäre Onkologie & Hämatologie". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Praxis für interdisziplinäre Onkologie & Hämatologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Praxis für interdisziplinäre Onkologie & Hämatologie, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Praxis für interdisziplinäre Onkologie & Hämatologie has several departments that took part in Clinical trials: "Praxis für Interdisziplinäre Onkologie und Hämatologie GbR" - 11 trials